Lupin announced that it has received approval from Health Canada for its biosimilar Pegfilgrastim. This product will be marketed under the brand name Armlupeg and manufactured at Lupin’s Biotech facility in Pune, India.
Lupin Q1 FY25 profit up 77% at Rs. 801 Cr
New Delhi: Shares of drug maker Lupin on Wednesday jumped over 6 per cent after .. nnRead more at: nhttps://health.economictimes.indiatimes.com/news/pharma/financial-performance/lupin-shares-jump-over-6-pc-hit-52-week-high-after-strong-june-qtr-earnings/112339536?utm_source=top_news&utm_medium=sectionListing
The study has achieved its primary endpoint of therapeutic equivalence in visual acuity improvement for wet AMD patients, showcasing comparable safety and immunogenicity between LUBT010 and Lucentis
Lupin receives USFDA approval for Prednisolone Acetate Ophthalmic Suspension USP
Lupin`s Generics Prednisolone Acetate Receives Approval in US
Global pharma major Lupin Limited announced that it has received tentative approval from the United States Food and Drug Administration (FDA) under the US President's Emergency Plan for AIDS Relief (PEPFAR) for its Abbreviated New Drug Application for emtricitabine and tenofovir alafenamide tablets, 200 mg/25 mg, to market a generic equivalent of Descovy tablets, 200 mg/25 mg, of Gilead Sciences, Inc.
The UK Medicines and Healthcare products Regulatory Agency (MHRA)’s novel approval means that certain patients with HIV have more options for treatment.
Global pharma major Lupin Limited (Lupin) announced that it has signed a license and supply agreement with Huons Co. for the registration and marketing of Cyclosporine Ophthalmic Nanoemulsion, 0.4mL Single-use Vial, in Mexico.
MUMBAI, India and NAPLES, Fla. and SAN DIEGO, July 15, 2024 /PRNewswire/ -- Global pharma major Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) announced today that it has divested its U.S. Commercial Women's Health Specialty Business to Evofem Biosciences, Inc. (OTCQB: EVFM) (Evofem), a U.S. biopharmaceutical company focused exclusively on Women's Health. Lupin's U.S. Commercial Women's Health Specialty Business is primarily focused on commercializing SOLOSEC® (secnidazole) 2g oral granules. This FDA-approved single-dose antimicrobial agent provides a complete course of therapy for the treatment of bacterial vaginosis (BV) and trichomoniasis, two common sexual health infections.